Compare · ANTX vs NVO
ANTX vs NVO
Side-by-side comparison of AN2 Therapeutics Inc. (ANTX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANTX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 1008.8x ANTX ($213.6M).
- Over the past year, ANTX is up 393.0% and NVO is down 12.1% - ANTX leads by 405.1 points.
- NVO has been more active in the news (9 items in the past 4 weeks vs 6 for ANTX).
- NVO has more recent analyst coverage (25 ratings vs 13 for ANTX).
- Company
- AN2 Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $5.64+0.62%
- $48.65+3.65%
- Market cap
- $213.6M
- $215.46B
- 1M return
- +14.62%
- -2.08%
- 1Y return
- +393.01%
- -12.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 6
- 9
- Recent ratings
- 13
- 25
AN2 Therapeutics Inc.
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ANTX
- AN2 Therapeutics Appoints Cameron Trenor, M.D., as Chief Medical Officer
- Director Readnour Robin Shane sold $212,702 worth of shares (35,402 units at $6.01) as part of a pre-agreed trading plan (SEC Form 4)
- Director Zakrzewski Joseph S gifted 405,880 shares (SEC Form 4)
- SEC Form 10-Q filed by AN2 Therapeutics Inc.
- AN2 Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights
- Director Aziz Kabeer was granted 2,852 shares, increasing direct ownership by 5% to 59,106 units (SEC Form 4)
- Director Marks Gilbert Lynn was granted 2,789 shares, increasing direct ownership by 4% to 81,873 units (SEC Form 4)
- Director Martin Patricia A. was granted 766 shares, increasing direct ownership by 4% to 18,863 units (SEC Form 4)
- Officer Eizen Joshua M sold $24,803 worth of shares (5,945 units at $4.17), decreasing direct ownership by 3% to 206,554 units (SEC Form 4) to satisfy tax liability
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S